Financial Contrast: Orchestra BioMed (NASDAQ:OBIO) vs. Acutus Medical (NASDAQ:AFIB)

Orchestra BioMed (NASDAQ:OBIO) and Acutus Medical (NASDAQ:AFIB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.

Institutional and Insider Ownership

53.6% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 56.9% of Acutus Medical shares are owned by institutional investors. 6.7% of Orchestra BioMed shares are owned by company insiders. Comparatively, 5.2% of Acutus Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Orchestra BioMed and Acutus Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-2,179.33%	-107.04%	-70.88%
Acutus Medical	-272.74%	-311.64%	-11.57%

Valuation & Earnings

This table compares Orchestra BioMed and Acutus Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$2.76 million	74.92	-$49.12 million	($1.61)	-3.38
Acutus Medical	$7.16 million	0.26	-$81.66 million	N/A	N/A

Orchestra BioMed has higher earnings, but lower revenue than Acutus Medical.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Orchestra BioMed and Acutus Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0	0	4	0	3.00
Acutus Medical	0	0	0	0	0.00

Orchestra BioMed presently has a consensus price target of $15.75, suggesting a potential upside of 189.52%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Acutus Medical.

Summary

Orchestra BioMed beats Acutus Medical on 7 of the 11 factors compared between the two stocks.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

About Acutus Medical

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.